January 23, 2026

Inventiva S.A. (IVA) Stock Analysis: Exploring a 108.61% Potential Upside with Strong Buy Ratings

Inventiva S.A. (IVA), a French biotechnology company listed on the American Depositary Receipt (ADR) market, is capturing investor attention with its promising pipeline and compelling analyst endorsements. With a current..

SIGA Technologies Inc. (SIGA): Valuation Insights and Growth Potential Amidst Healthcare Sector Challenges

Investors eyeing opportunities in the healthcare sector might find SIGA Technologies Inc. (NASDAQ: SIGA) an intriguing prospect. With a market capitalization of $481.94 million, this New York-based pharmaceutical company is..

Cross Country Healthcare, Inc. (CCRN) Stock Analysis: Navigating Challenges with an 8.08% Upside Potential

Investors examining Cross Country Healthcare, Inc. (NASDAQ: CCRN) are evaluating a company deeply rooted in the healthcare sector, specifically within the medical care facilities industry. Based in Boca Raton, Florida,..

Replimune Group, Inc. (REPL) Stock Analysis: A 59% Potential Upside in Oncolytic Immunotherapy

Investors looking to tap into the burgeoning field of biotechnology may find Replimune Group, Inc. (REPL) an intriguing prospect. This clinical-stage company, with a market cap of $619.7 million, is..

Talkspace, Inc. (TALK) Investor Outlook: 25.94% Potential Upside and Strong Buy Ratings Highlight Growth Potential

Talkspace, Inc. (NASDAQ: TALK), a pioneering force in the virtual behavioral healthcare sector, is capturing the attention of investors thanks to its impressive potential upside and a strong lineup of..

Simulations Plus, Inc. (SLP): Investor Outlook and Analyst Consensus Reveal 18.76% Upside Potential

Simulations Plus, Inc. (NASDAQ: SLP), a notable player in the Healthcare sector specializing in Health Information Services, presents a compelling case for investors seeking exposure to innovative solutions in drug..

Fortrea Holdings Inc. (FTRE) Stock Analysis: Navigating Volatility with Strategic Growth in Biotech

Fortrea Holdings Inc. (NASDAQ: FTRE), a burgeoning player in the healthcare sector, is making waves in the biotechnology industry. With a market cap of $1.6 billion, this U.S.-based contract research..

Ginkgo Bioworks Holdings, Inc. (DNA) Stock Analysis: Navigating Challenges in the Biotech Sector

Ginkgo Bioworks Holdings, Inc. (NASDAQ: DNA), a promising player in the biotechnology sector, is making waves with its innovative approach to cell programming and biosecurity. Despite the turbulent market conditions,..

MeiraGTx Holdings plc (MGTX) Stock Analysis: Exploring a 221.90% Potential Upside in the Biotech Space

MeiraGTx Holdings plc (NASDAQ: MGTX), a clinical-stage gene therapy company, stands at an intriguing intersection of innovation and investment opportunity. With a market capitalization of $668.88 million, the company is..

Zenas BioPharma (ZBIO) Stock Analysis: Promising 99.75% Upside Potential for Investors

Zenas BioPharma, Inc. (NASDAQ: ZBIO) is capturing the attention of investors with its significant upside potential, underscored by a 99.75% potential gain based on current analyst target prices. As a..

STAAR Surgical Company (STAA) Investor Outlook: Assessing the 21% Potential Upside

STAAR Surgical Company (NASDAQ: STAA), a key player in the healthcare sector, specifically in the medical instruments and supplies industry, has been a subject of significant interest among investors. The..

Theravance Biopharma, Inc. (TBPH) Investor Outlook: Unveiling a 28.81% Potential Upside

Theravance Biopharma, Inc. (NASDAQ: TBPH) is making waves in the biotechnology sector, sporting a market capitalization of $1.05 billion. Based in South San Francisco, California, this innovative company focuses on..

Enliven Therapeutics (ELVN) Stock Analysis: A 53% Upside Potential with Strong Analyst Support

Enliven Therapeutics, Inc. (NASDAQ: ELVN) has captured the attention of investors with its promising potential, particularly in the cutting-edge field of biotechnology. As a clinical-stage biopharmaceutical company, Enliven is dedicated..

AnaptysBio, Inc. (ANAB) Stock Analysis: Biotechnology Innovator with 43.50% Upside Potential

AnaptysBio, Inc. (ANAB), a San Diego-based biotechnology company, is making waves in the healthcare sector with its promising portfolio of immunology therapeutics. With a market capitalization of $1.32 billion, this..

Orthofix Medical Inc. (OFIX) Investor Outlook: Exploring a 64.86% Potential Upside in Medical Devices

Orthofix Medical Inc. (NASDAQ: OFIX), a prominent player in the medical technology sector, has caught the attention of investors with a potential upside of 64.86%, according to recent analyst ratings...

Sana Biotechnology, Inc. (SANA)

⚠️ No article content returned.

..

Mind Medicine (MNMD) Stock Analysis: A Biotech Play with a 90% Potential Upside

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) presents a compelling narrative for investors interested in the biotechnology sector, particularly those focusing on innovative treatments for brain health disorders. With a market..

Xencor, Inc. (XNCR) Stock Analysis: A Biotech Contender with 119.93% Potential Upside

Xencor, Inc. (NASDAQ: XNCR) is making waves in the biotechnology sector with a promising portfolio of monoclonal antibody treatments targeting a range of critical health issues, from autoimmune diseases to..

Sionna Therapeutics, Inc. (SION) Stock Analysis: Exploring a 7.39% Potential Upside in Biotech Innovation

Sionna Therapeutics, Inc. (NASDAQ: SION), a clinical-stage biopharmaceutical firm, has captured investor attention with its focus on developing innovative treatments for cystic fibrosis (CF). With a market capitalization of $1.86..

Arbutus Biopharma (ABUS) Stock Analysis: Exploring a Potential 37% Upside in the Biotech Sector

Arbutus Biopharma Corporation (NASDAQ: ABUS), a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for infectious diseases, has captured the interest of investors with its substantial potential upside. Currently trading..

Search

Funds

January 23, 2026

Search

Funds

January 23, 2026

FTSE 100

Funds